Hisamitsu Pharmaceut (HTSUF) 56.3000 $HTSUF
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 10.90 (+0.35)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.37 (-0.02), PFE: 34.47 (+0.25), AMGN: 151.26 (+1.64), ZYNE: 7.60 (+0.05), NKTR: 15.27 (+0.42), AZN: 28.57 (+0.99), VBAY: (), PTIE: 2.10 (+0.07)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.33 (+0.03), MDGN: 6.34 (+0.36), ADHD: 4.34 (+0.09), SUPN: 18.23 (+0.41), COLL: 14.23 (-0.04), DRRX: 1.25 (+0.05), NEOS: 10.02 (+0.14), NDRM: 16.89 (+0.17), MRK: 56.47 (+0.58), SHPG: 175.58 (+6.76), ITCI: 39.21 (+1.78)
Low Back Pain - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/w4jxdk/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Low Back Pain Overview - Therapeutics Development - Pipeline Products for Low Back Pain - Overview - Pipeline Products for Low Back Pain - Comparative Analysis - Low Back Pain - Therapeutics under Development by Companies - Low Back Pain - Therapeutics under Investigation by Universities/Institutes - Low Back Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Low Back Pain - Products under Development by Companies - Low Back Pain - Products under Investigation by Universities/Institutes - Low Back Pain - Companies Involved in Therapeutics Development - Adynxx, Inc. - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immune Pharmaceuticals Inc. - Ipsen S.A. - MEDRx Co., Ltd. - Mesoblast Limited - Nektar Therapeutics - Orion Oyj - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Stayble Therapeutics For more information visit http://www.researchandmarkets.com/research/w4..._back_pain
MESO: 4.10 (+0.20), PFE: 34.47 (+0.25), IMNP: 0.44 (+0.03), LLY: 74.22 (+0.36), PCRX: 38.24 (-0.36), NKTR: 15.27 (+0.42)
Noven Announces Appointment of Jeff Mihm as Chief Executive Officer
BusinessWire - Tue Jan 05, 1:31PM CST
--Michael Greene Appointed Vice President, General Counsel & Corporate Secretary
Hisamitsu Pharmaceutical Co., Inc. - Product Pipeline Review - 2015
M2 - Fri Dec 18, 6:23AM CST
Acute Market Reports's, 'Hisamitsu Pharmaceutical Co., Inc. - Product Pipeline Review - 2015', provides an overview of the Hisamitsu Pharmaceutical Co., Inc.'s pharmaceutical research and development focus.
Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015 - Analysis, Trends, Technologies & Forecast Report
M2 - Tue Dec 08, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc5r36/myofascial_pain) has announced the addition of the "Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015" provides an overview of Myofascial Pain Syndromes clinical trials scenario. This report provides top line data relating to the clinical trials on Myofascial Pain Syndromes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Ipsen S.A. - Allergan Plc - Laboratorio Brasileiro de Biologia - IBSA Institut Biochimique SA - Hisamitsu Pharmaceutical Co., Inc. - Fundacao Amparo a Pesquisa do Estado Sao Paulo - Boston Urogynecology Associates - Biotest AG For more information visit http://www.researchandmarkets.com/research/mc...scial_pain
AGN: 235.87 (+0.82)
Restless Legs Syndrome Pipeline Review, H2 2015 - 8 Companies & 8 Drug Profiles
M2 - Tue Sep 22, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m55jdp/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Mundipharma International Ltd - Omeros Corporation - Serina Therapeutics, Inc. - Vifor Pharma AG Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - aplindore fumarate - AZ-008 - ferric carboxymaltose - OMS-527 - pramipexole dihydrochloride - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/m5...tless_legs
ASND: 13.91 (-0.06), OMER: 10.90 (+0.35)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 4.33 (+0.03), ADHD: 4.34 (+0.09), SUPN: 18.23 (+0.41), COLL: 14.23 (-0.04), LLY: 74.22 (+0.36), DRRX: 1.25 (+0.05), NEOS: 10.02 (+0.14), NDRM: 16.89 (+0.17), CERC: 2.49 (-0.01), SHPG: 175.58 (+6.76), MRK: 56.47 (+0.58), ITCI: 39.21 (+1.78)
Restless Legs Syndrome Therapeutics Pipeline Review 2015 - 7 Companies & 7 Drug Profiles
M2 - Wed Mar 11, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqjzpr/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Omeros Corporation - Purdue Pharma L.P. - Serina Therapeutics, Inc. Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - ACP-006 - aplindore fumarate - AZ-008 - OMS-527 - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/mq...tless_legs
ASND: 13.91 (-0.06), OMER: 10.90 (+0.35)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 4.34 (+0.09), PFE: 34.47 (+0.25), SUPN: 18.23 (+0.41), LLY: 74.22 (+0.36), DRRX: 1.25 (+0.05), NDRM: 16.89 (+0.17), SHPG: 175.58 (+6.76), ITCI: 39.21 (+1.78)
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 10.90 (+0.35)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.37 (-0.02), PFE: 34.47 (+0.25), AMGN: 151.26 (+1.64), ZYNE: 7.60 (+0.05), NKTR: 15.27 (+0.42), AZN: 28.57 (+0.99), VBAY: (), PTIE: 2.10 (+0.07)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.33 (+0.03), MDGN: 6.34 (+0.36), ADHD: 4.34 (+0.09), SUPN: 18.23 (+0.41), COLL: 14.23 (-0.04), DRRX: 1.25 (+0.05), NEOS: 10.02 (+0.14), NDRM: 16.89 (+0.17), MRK: 56.47 (+0.58), SHPG: 175.58 (+6.76), ITCI: 39.21 (+1.78)
Low Back Pain - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/w4jxdk/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Low Back Pain Overview - Therapeutics Development - Pipeline Products for Low Back Pain - Overview - Pipeline Products for Low Back Pain - Comparative Analysis - Low Back Pain - Therapeutics under Development by Companies - Low Back Pain - Therapeutics under Investigation by Universities/Institutes - Low Back Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Low Back Pain - Products under Development by Companies - Low Back Pain - Products under Investigation by Universities/Institutes - Low Back Pain - Companies Involved in Therapeutics Development - Adynxx, Inc. - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immune Pharmaceuticals Inc. - Ipsen S.A. - MEDRx Co., Ltd. - Mesoblast Limited - Nektar Therapeutics - Orion Oyj - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Stayble Therapeutics For more information visit http://www.researchandmarkets.com/research/w4..._back_pain
MESO: 4.10 (+0.20), PFE: 34.47 (+0.25), IMNP: 0.44 (+0.03), LLY: 74.22 (+0.36), PCRX: 38.24 (-0.36), NKTR: 15.27 (+0.42)
Noven Announces Appointment of Jeff Mihm as Chief Executive Officer
BusinessWire - Tue Jan 05, 1:31PM CST
--Michael Greene Appointed Vice President, General Counsel & Corporate Secretary
Hisamitsu Pharmaceutical Co., Inc. - Product Pipeline Review - 2015
M2 - Fri Dec 18, 6:23AM CST
Acute Market Reports's, 'Hisamitsu Pharmaceutical Co., Inc. - Product Pipeline Review - 2015', provides an overview of the Hisamitsu Pharmaceutical Co., Inc.'s pharmaceutical research and development focus.
Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015 - Analysis, Trends, Technologies & Forecast Report
M2 - Tue Dec 08, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc5r36/myofascial_pain) has announced the addition of the "Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Myofascial Pain Syndromes Global Clinical Trials Review, H2, 2015" provides an overview of Myofascial Pain Syndromes clinical trials scenario. This report provides top line data relating to the clinical trials on Myofascial Pain Syndromes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Ipsen S.A. - Allergan Plc - Laboratorio Brasileiro de Biologia - IBSA Institut Biochimique SA - Hisamitsu Pharmaceutical Co., Inc. - Fundacao Amparo a Pesquisa do Estado Sao Paulo - Boston Urogynecology Associates - Biotest AG For more information visit http://www.researchandmarkets.com/research/mc...scial_pain
AGN: 235.87 (+0.82)
Restless Legs Syndrome Pipeline Review, H2 2015 - 8 Companies & 8 Drug Profiles
M2 - Tue Sep 22, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m55jdp/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Mundipharma International Ltd - Omeros Corporation - Serina Therapeutics, Inc. - Vifor Pharma AG Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - aplindore fumarate - AZ-008 - ferric carboxymaltose - OMS-527 - pramipexole dihydrochloride - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/m5...tless_legs
ASND: 13.91 (-0.06), OMER: 10.90 (+0.35)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 4.33 (+0.03), ADHD: 4.34 (+0.09), SUPN: 18.23 (+0.41), COLL: 14.23 (-0.04), LLY: 74.22 (+0.36), DRRX: 1.25 (+0.05), NEOS: 10.02 (+0.14), NDRM: 16.89 (+0.17), CERC: 2.49 (-0.01), SHPG: 175.58 (+6.76), MRK: 56.47 (+0.58), ITCI: 39.21 (+1.78)
Restless Legs Syndrome Therapeutics Pipeline Review 2015 - 7 Companies & 7 Drug Profiles
M2 - Wed Mar 11, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqjzpr/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Omeros Corporation - Purdue Pharma L.P. - Serina Therapeutics, Inc. Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - ACP-006 - aplindore fumarate - AZ-008 - OMS-527 - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/mq...tless_legs
ASND: 13.91 (-0.06), OMER: 10.90 (+0.35)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 4.34 (+0.09), PFE: 34.47 (+0.25), SUPN: 18.23 (+0.41), LLY: 74.22 (+0.36), DRRX: 1.25 (+0.05), NDRM: 16.89 (+0.17), SHPG: 175.58 (+6.76), ITCI: 39.21 (+1.78)
